This traditional preparation is commonly used for managing symptoms related to irritation and dryness in the upper respiratory tract. Its traditional use is for the symptomatic treatment of oral or pharyngeal irritation and associated dry cough.

The product is relevant for managing symptom clusters that may appear when patients experience vocal strain, which may include hoarseness and huskiness. It is applied across domains where additional symptomatic support is needed, generally helping to ease the physiological strain and supporting the maintenance of general well-being during symptomatic phases.

Contextual Use and Symptom Focus

The medicine is commonly applied in clinical settings marked by heightened irritation of the mouth and throat mucous membranes, which may present as a scratchy, burning, or itching sensation, and may assist with managing the dry, tickling cough that frequently accompanies such discomfort. This product is commonly applied in situations where symptoms are caused by environmental factors, such as exposure to dry ambient air (e.g., heated rooms, flying) or professional circumstances involving high dust exposure. It helps address groups of symptoms that may appear suddenly, offering symptomatic assistance, which contributes to improved comfort.

Quick Fact: Relief for Irritative Cough

Regulatory References

1. European Medicines Agency

The eligibility criteria for using the Iceland lichen extract product, Исла Моос, are explicitly documented in official regulatory sources, defining who is permitted to use the medicine and who must abstain. Use is documented as acceptable for Adults, Adolescents, and the Elderly population.

Contraindications and Restrictions

The following rules determine non-eligibility, based on official regulatory classifications:

Category	Official Regulatory Rule
Absolute Contraindication	Hypersensitivity to the active substance (Iceland lichen extract) or any excipient is an absolute bar to use.
Age-Related Rule	The solid dosage form is not recommended for children under 6 years of age. This restriction is based on the pharmaceutical form due to the potential risk of choking.
Maternal Status	Use is not recommended during pregnancy or lactation. This status is due to a formal regulatory finding that safety has not been established in the absence of sufficient data.
Comorbidity Warning	Individuals with certain sugar intolerances (such as hereditary fructose intolerance) must exercise caution, as the lozenges contain sucrose.

This official eligibility profile is structured by formal constraints: an absolute ban for individuals with hypersensitivity, specific age restrictions related to the physical product form, and a cautious "not recommended" status for maternal use due to a documented data gap.

Interactions with other medicines and products

The official regulatory profile for Iceland lichen extract lozenges is characterized by a single, physical interaction pattern, as documented in authoritative regulatory sources like the European Medicines Agency (EMA).

Due to the medicine's demulcent property, the polysaccharides in the extract form a protective mucilage film. Co-administration with other orally administered medicinal products may, therefore, cause pharmacokinetic interference, specifically resulting in the delay of absorption of the co-administered drug.

To prevent this documented effect, official labeling specifies a mandatory administration-timing rule. The product should not be taken frac12 to 1 hour before or after the intake of any other medicinal product intended for oral use. This constraint is the primary interaction-related restriction defined in the regulatory documentation.

Crucially, no systemic interactions are officially documented. The regulatory information confirms the absence of formal contraindicated combinations and does not identify any metabolic (CYP-mediated), transporter-based (P-gp), or pharmacodynamic interactions with other substances. The profile is limited to the physical necessity of separating administration from other oral medicines.

Creating a Localized Protective Film

The mechanism is based on the physical properties of the product's mucilage content, which comprises complex carbohydrate polymers. When introduced to moisture, these polymers swell to form a highly viscous, gel-like coating that adheres directly to the mucous membranes of the mouth and throat. This action creates a localized physical barrier and results in a higher local surface moisture level, thereby mechanically reducing the contact of the tissue surface with external friction.

---

Shielding the Sensory Endings

By establishing a physical barrier, the mechanism acts to insulate the sensitive underlying afferent sensory nerve endings from external stimuli (chemical or mechanical). This is a peripheral action that physically impedes the stimuli from reaching the neural receptors. The primary physiological consequence is the attenuation of sensory nerve afferent signaling originating from the local site, which influences the regulation of mucosal surface responsiveness. The resulting physiological effect is the maintenance of tissue surface integrity and the reduction in external stimulus-induced afferent signaling.

How to Use Исла Моос

Administration of Исла Моос lozenges follows a specific, standardized protocol established for the plant extract.

Administration Scope

Instruction	Detail
Route of Administration:	Oromucosal use, intended for local action on the mucous membranes of the mouth and throat.
Dosing Schedule:	Adults, adolescents, and the elderly take a specific single dose of the soft extract, repeating the administration several times daily as needed. The maximum daily intake is capped at a defined level, such as up to 2 grams of soft extract (depending on the product's concentration).
Age-Group Rules:	Use is not recommended for children under 6 years of age due to the solid nature of the lozenge dosage form. Children aged 6 to 12 follow a reduced daily regimen, typically administered 4 to 6 times daily.
Special Conditions:	A mandatory interval of 1/2 to 1 hour must be observed between the administration of the lozenges and the intake of any other oral medicinal products. This constraint is stipulated to prevent the extract from potentially delaying the absorption of other co-administered medicines.

---

Course Duration and Procedural Structure

The lozenge is intended for short-term, symptomatic use. The administration method requires that the lozenge be allowed to dissolve slowly in the mouth to facilitate the local, physical protective action of the Iceland lichen extract. If symptoms persist or worsen after one week of use, the treatment course requires review.

The official instructions establish the necessity of repeating the dose several times daily to maintain the desired physical effect. This protocol defines the product as a symptom-contingent application with a clear time boundary.

Overview of Clinical Research

Исла Моос lozenges contain an extract of Iceland moss (Cetraria islandica), a lichen traditionally used for its soothing properties. The primary focus of clinical evaluation is the relief of symptoms related to irritation of the mouth and throat, and associated dry cough.

Mechanism of Action (Mucilage Content)

The therapeutic actions of Iceland moss are primarily attributed to its high content of mucilage (polysaccharides). When dissolved, these substances form a protective layer over the mucous membranes of the oral cavity and pharynx. This physical barrier may help to shield irritated tissues from external irritants and aid in the relief of hoarseness and throat dryness.

Summary of Outcomes

Regulatory agencies, such as the European Medicines Agency (EMA), have recognized the use of Iceland moss extract for treating mouth and throat irritation and the accompanying dry cough. This assessment is based on sufficient evidence of long-standing traditional use, supported by data from post-marketing surveillance studies.

One large, multi-center surveillance study involving over 3,000 children with upper respiratory tract conditions, including cough, evaluated Iceland moss lozenges over a period of 1 to 2 weeks. The study documented a favorable safety and tolerability profile. By the end of the observation period, investigators reported that 39% of the children were fully recovered, and an additional 55% showed improvement in clinical symptoms. The incidence of adverse drug reactions was reported to be very low, suggesting good local tolerance in the studied population.

Common questions about Исла Моос (FAQ)

Q: Is Исла Моос the same as Icelandic moss?

According to the official product information, Исла Моос contains an aqueous extract of the lichen known as Icelandic moss (Cetraria islandica). Therefore, the medicine is a formulated preparation derived from the plant, and not the raw, unprocessed plant material itself. Its effects are attributed to the properties of this specific extract.

Q: Can Исла Моос be used for a wet cough?

Regulatory authorities recognize the medicine for the symptomatic relief of throat irritation and the associated dry cough. Its physical mechanism creates a protective film to soothe irritated membranes. Official documents do not include recommendations or specific data regarding the use of the product for a cough that is not dry or irritative.

Q: Is a slight stomach upset a known side effect of Исла Моос?

The safety profile, which is based on the traditional long-standing use of the active ingredient, indicates that no undesirable effects are known in connection with its approved indications. This means that a specific incidence of minor issues like stomach upset is not documented in the official regulatory safety information.

Q: Can people with diabetes use Исла Моос?

The lozenges contain sucrose, which is a sugar. Because of this ingredient, individuals with pre-existing conditions that affect blood sugar regulation, such as diabetes, should review the ingredient list with a healthcare professional.

Q: Does Исла Моос contain sugar or any artificial sweeteners?

Official documentation confirms that sucrose (a sugar) is present as an excipient in the lozenges. Information on whether the product contains any specific artificial sweeteners is typically detailed in the official list of non-active components provided by the manufacturer.

Q: Does using Исла Моос affect my ability to drive?

The official safety documentation does not include warnings that the medicine affects the ability to drive or operate machinery. The regulatory profile is limited to local action, and no central nervous system effects are documented.

Q: Are there long-term effects from using Исла Моос regularly?

The medicine is approved for short-term, symptomatic use, which is documented as lasting for approximately one week before an assessment of the treatment course is advised. The regulatory profile and safety assessment are based on use within this recommended duration, and data on the effects of continuous, long-term use is limited.

Q: Is Исла Моос recommended for general voice care?

Official documents recognize the medicine for the symptomatic relief of throat irritation and hoarseness, often linked to vocal strain. Its documented purpose is to soothe existing symptoms, and is not officially defined as a treatment for general or preventative voice care.

Q: What should I do if I experience a rash after using Исла Моос?

A rash may be a sign of hypersensitivity, which is the medical term for an allergic reaction. In the event a person suspects an adverse reaction, the standard safety protocol involves stopping use of the product and consulting a doctor or pharmacist for advice.

Q: Does Исла Моос affect blood pressure?

The action of the medicine is entirely local and physical on the mucous membranes of the mouth and throat. Official documentation confirms that there are no systemic interactions documented, meaning the product is not expected to affect internal physiological processes like blood pressure.

Q: Can people with thyroid conditions use Исла Моос?

The product has a local, physical action. Official documentation confirms that no systemic interactions or specific warnings for thyroid conditions are documented.

Q: Is there any known interaction between Исла Моос and alcohol?

The only documented interaction is a physical interference with the absorption of other oral medicinal products, due to the mucilage film. No systemic interactions are documented, and the official regulatory profile does not specify any interaction between the medicine and consumed alcohol.

Q: Is the main ingredient in Исла Моос a known allergen?

The official regulatory safety framework identifies a known hypersensitivity to the active substance (Iceland lichen extract) or any excipient as an absolute contraindication for use. This means that a history of allergy to the specific components is the only absolute restriction defined by regulators.

How to Store and Dispose of Исла Моос

Official regulatory documents define specific, non-advisory requirements for the storage, handling, and disposal of Исла Моос lozenges. These instructions ensure product quality is maintained until the expiry date.

Required Storage Conditions

Requirement	Official Regulatory Statement
Temperature	Store at a temperature that does not exceed 25°C.
Protection	Keep the product in a dry place to protect it from moisture.
Child Safety	Must be kept out of the sight and reach of children.
Packaging	Keep the lozenges in the original primary packaging until use.

Stability and Disposal

The product must not be used after the expiry date printed on the container. No specific in-use stability period after opening is documented in public summaries for this product. Disposal of unused or expired lozenges should follow local pharmaceutical or household waste regulations, as no specific environmental or hazardous-waste instructions are typically provided in the official labeling.